AU2007334039B2 - Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer - Google Patents

Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer Download PDF

Info

Publication number
AU2007334039B2
AU2007334039B2 AU2007334039A AU2007334039A AU2007334039B2 AU 2007334039 B2 AU2007334039 B2 AU 2007334039B2 AU 2007334039 A AU2007334039 A AU 2007334039A AU 2007334039 A AU2007334039 A AU 2007334039A AU 2007334039 B2 AU2007334039 B2 AU 2007334039B2
Authority
AU
Australia
Prior art keywords
benzo
thiophen
ethyl
imidazolidin
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007334039A
Other languages
English (en)
Other versions
AU2007334039A1 (en
Inventor
Harold Burns Brooks
Joyce Z. Crich
James Robert Henry
Hong-Yu Li
Melissa Kate Slater
Yan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2007334039A1 publication Critical patent/AU2007334039A1/en
Application granted granted Critical
Publication of AU2007334039B2 publication Critical patent/AU2007334039B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007334039A 2006-12-21 2007-12-11 Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer Ceased AU2007334039B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87130206P 2006-12-21 2006-12-21
US60/871,302 2006-12-21
PCT/US2007/087044 WO2008076704A1 (en) 2006-12-21 2007-12-11 Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer

Publications (2)

Publication Number Publication Date
AU2007334039A1 AU2007334039A1 (en) 2008-06-26
AU2007334039B2 true AU2007334039B2 (en) 2012-02-16

Family

ID=39186811

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007334039A Ceased AU2007334039B2 (en) 2006-12-21 2007-12-11 Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer

Country Status (14)

Country Link
US (1) US8101628B2 (cg-RX-API-DMAC10.html)
EP (1) EP2125793B1 (cg-RX-API-DMAC10.html)
JP (1) JP5166441B2 (cg-RX-API-DMAC10.html)
KR (1) KR101088291B1 (cg-RX-API-DMAC10.html)
CN (1) CN101563342B (cg-RX-API-DMAC10.html)
AT (1) ATE479680T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007334039B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0721045A2 (cg-RX-API-DMAC10.html)
CA (1) CA2671738A1 (cg-RX-API-DMAC10.html)
DE (1) DE602007008952D1 (cg-RX-API-DMAC10.html)
EA (1) EA016177B1 (cg-RX-API-DMAC10.html)
ES (1) ES2349169T3 (cg-RX-API-DMAC10.html)
MX (1) MX2009006634A (cg-RX-API-DMAC10.html)
WO (1) WO2008076704A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2125794T1 (sl) 2006-12-21 2011-02-28 Lilly Co Eli Spojine imidazolidinonil aminopirimidina za zdravljenje raka
EA016781B1 (ru) * 2007-05-16 2012-07-30 Эли Лилли Энд Компани Триазолиламинопиримидиновые соединения
WO2008144222A2 (en) 2007-05-16 2008-11-27 Eli Lilly And Company Triazolyl aminopyrimidine compounds
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929726A (en) 1988-02-09 1990-05-29 Georgia State University Foundation, Inc. Novel diazines and their method of preparation
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
WO2004063192A1 (en) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
JP2007533602A (ja) * 2003-07-31 2007-11-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾチオフェン化合物及びそれらの使用
AU2005316312B2 (en) 2004-12-17 2009-10-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
TW200800201A (en) * 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
SI2125794T1 (sl) 2006-12-21 2011-02-28 Lilly Co Eli Spojine imidazolidinonil aminopirimidina za zdravljenje raka
EA016781B1 (ru) 2007-05-16 2012-07-30 Эли Лилли Энд Компани Триазолиламинопиримидиновые соединения
WO2008144222A2 (en) 2007-05-16 2008-11-27 Eli Lilly And Company Triazolyl aminopyrimidine compounds

Also Published As

Publication number Publication date
MX2009006634A (es) 2009-06-30
EA016177B1 (ru) 2012-02-28
KR101088291B1 (ko) 2011-11-30
AU2007334039A1 (en) 2008-06-26
BRPI0721045A2 (pt) 2014-07-29
US20100076001A1 (en) 2010-03-25
WO2008076704A1 (en) 2008-06-26
ES2349169T3 (es) 2010-12-28
KR20090086114A (ko) 2009-08-10
EA200970615A1 (ru) 2009-10-30
CN101563342A (zh) 2009-10-21
ATE479680T1 (de) 2010-09-15
US8101628B2 (en) 2012-01-24
JP2010513552A (ja) 2010-04-30
EP2125793B1 (en) 2010-09-01
CA2671738A1 (en) 2008-06-26
EP2125793A1 (en) 2009-12-02
CN101563342B (zh) 2012-09-05
JP5166441B2 (ja) 2013-03-21
DE602007008952D1 (de) 2010-10-14

Similar Documents

Publication Publication Date Title
AU2008254319B2 (en) Triazolyl aminopyrimidine compounds
AU2007334040B2 (en) Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
AU2008254318B2 (en) Triazolyl aminopyrimidine compounds
US8101628B2 (en) Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired